Axsome settles SUNOSI patent litigation with Hetero; generic entry delayed until 2040

Axsome Therapeutics, Inc.

Settlement resolves patent litigation with Hetero over generic version of SUNOSI (solriamfetol).
Hetero licensed to sell generic SUNOSI on or after Sept 1, 2040 (if pediatric exclusivity) or March 1, 2040.
Settlement agreement subject to review by FTC and DOJ.
Similar patent litigation against other SUNOSI generic applicants remains pending in New Jersey court.

item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.